Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: viral RNA polymerase inhibitors - BioCryst

Drug Profile

Research programme: viral RNA polymerase inhibitors - BioCryst

Alternative Names: BCX-5191; BCX4678; Hepatitis C virus RNA polymerase inhibitors - BioCryst

Latest Information Update: 26 Feb 2013

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioCryst Pharmaceuticals; CNRS; Emory University
  • Developer BioCryst Pharmaceuticals
  • Class Nucleosides; Small molecules
  • Mechanism of Action DNA-directed RNA polymerase inhibitors; Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Ebola virus infections; Hepatitis C; West Nile virus infections

Most Recent Events

  • 31 Jan 2013 Discontinued - Preclinical for Hepatitis C in USA (PO)
  • 31 Jan 2013 BioCryst terminates preclinical trial in Hepatitis C virus infection in USA
  • 07 Dec 2012 BioCryst announces the company's strategic restructuring with focus on development of antiviral programmes, including BCX 5191 for HCV and a broad spectrum antiviral BCX 4430
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top